MedTrace Logo

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

NCT06863480 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-04

No results posted yet for this study

Summary

In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage
  • Delayed Cerebral Ischemia

Interventions

DRUG

tocilizumab-aazg (TYENNE)

A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Brian Hoh, MD · University of Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2028-07-30
Completion
2028-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06863480 on ClinicalTrials.gov